Dutch Court Nixes GSK Asthma Drug Patent

Law360, New York (January 27, 2011, 5:44 PM EST) -- A Dutch court has nixed GlaxoSmithKline PLC's extended patent protection for Seretide, siding with two Novartis AG generics units in a case over the blockbuster asthma treatment.

The District Court in the Hague ruled that the Dutch patent for the asthma treatment, marketed as Advair in the U.S., was no longer valid, GSK said Wednesday. The original patent had expired in September, but the company received a supplementary protection certificate in the Netherlands that granted it another three years of patent protection for the drug....
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.